Wire · opportunities
FDA Okays Once-Weekly Tx for Turner Syndrome Growth Failure
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 November 2026 · Fusion42 review
The FDA has approved the once-weekly long-acting growth hormone somapacitan-beco (Sogroya, Novo Nordisk) for treating growth failure in children aged 2.5 years and older with Turner syndrome. This new indication expands somapacitan-beco’s use beyond previous approvals for growth hormone deficiency and other pediatric growth conditions.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 20 Nov 2026 and 21 Nov 2026.
◆ ◆ The Wire takeaway
You can now offer a once-weekly injection to young patients with Turner syndrome, removing daily dosing barriers and opening your clinic to more compliant treatments. This marks a rare chance to differentiate in pediatric endocrinology with better patient adherence.
◆ Coverage
2 sources · first reported 20 Nov 2026 · latest 21 Nov 2026
◆ Related on Wire
◆ Topics